- Home
- IEX vs NBIX Comparison
IEX vs NBIX Comparison
Compare IEX & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IEX | NBIX |
|---|---|---|
| Founded | 1987 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 14.4B |
| IPO Year | 1991 | 1996 |
Fundamental Metrics
Financial Performance| Metric | IEX | NBIX |
|---|---|---|
| Price | $178.52 | $152.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 20 |
| Target Price | ★ $196.00 | $175.10 |
| AVG Volume (30 Days) | 625.0K | ★ 938.9K |
| Earning Date | 02-03-2026 | 10-28-2025 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | N/A | ★ 12.44 |
| EPS | ★ 6.32 | 4.19 |
| Revenue | ★ $3,421,300,000.00 | $2,682,700,000.00 |
| Revenue This Year | $6.31 | $23.76 |
| Revenue Next Year | $2.96 | $18.01 |
| P/E Ratio | ★ $28.31 | $36.45 |
| Revenue Growth | 7.09 | ★ 19.61 |
| 52 Week Low | $153.36 | $84.23 |
| 52 Week High | $228.88 | $160.18 |
Technical Indicators
Market Signals| Indicator | IEX | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 60.05 | 56.82 |
| Support Level | $173.03 | $151.09 |
| Resistance Level | $183.05 | $156.70 |
| Average True Range (ATR) | 3.17 | 4.19 |
| MACD | 0.37 | 0.11 |
| Stochastic Oscillator | 58.89 | 60.72 |
Price Performance
Historical ComparisonAbout IEX IDEX Corporation
Idex manufactures pumps, flow meters, valves, and fluidic systems for customers in a variety of end markets, including industrial, fire and safety, life science, and water. The firm's business is organized into three segments: fluid and metering technologies, health and science technologies, and fire and safety and diversified products. Based in Lake Forest, Illinois, Idex has manufacturing operations in over 20 countries and has over 7,000 employees. The company generated $3.3 billion in revenue in 2024.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.